MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 500287-72-9
MCE 国际站:Rilpivirine
产品活性:Rilpivirine (R278474) 是一种有效和特异性的二芳基嘧啶 (DAPY) 非核苷逆转录酶抑制剂 (NNRTI)。Rilpivirine 对野生型 HIV (EC50=0.4 nM) 和突变体 (EC50=0.1-2.0 nM) 具有很高的抗病毒活性。Rilpivirine 对 HIV 耐药性的形成产生了高度的遗传障碍。
研究领域:Anti-infection
作用靶点:HIV | Reverse Transcriptase
In Vitro: R278474 is active against wild-type HIV-1 (EC50=0.4 nM) and all single and double mutants tested (EC50=0.1-2.0 nM).
R278474 (10-5000 nM; 30 d) does not observe the sign of wild-type HIV-1 breakthrough at 1 μM within 30 days.
R278474 inhibits 81% of clinical isolates (about 1200 recombinant clinical isolates) at a 50% inhibitory concentration (EC50) less than 1 nM, and inhibits 94% at EC50 less than 10 nM.
TMC278 shows subnanomolar EC50s against wild-type HIV-1 group M isolates (0.07-1.01 nM) and nanomolar EC50s against group O isolates (2.88-8.45 nM) in MT4 T-cells.
In Vivo: R278474 (10-160 mg/kg; p.o. for 1 month) does not produce abnormal effects in rat, apart from liver weight increase and species-specific thyroid hypertrophy, both at the higher dose levels.
R278474 (i.v.) exhibits elimination half-life ranges from 4.4 h in rat to 31 h in dog, and exposure (AUCinf) amounts to 3.1 μg•h/mL (4 mg/kg) in rat, 8.7 μg•h/mL (1.25 mg/kg) in dog, 1.4 μg•h/mL (1.25 mg/ kg) in monkey, and 44•μg h/mL (1.25 mg/kg) in rabbit.
R278474 (p.o.) exhibits half-life ranges between 2.8 h in rat and 39 h in dog, and oral bioavailability of 32% and 31% in rat and dog.
相关产品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | Human Metabolite Library | Heterocyclic Compound Library | Off-patent Drug Library | Cysteine Targeted Covalent Library | Highly Selective Inhibitors Library | Peldesine dihydrochloride | Abacavir sulfate | HIV-IN-6 | Epicoccone B | Ditiocarb | Nevirapine | DAPTA | Aloperine | Elipovimab | HIV-1 inhibitor-52 | PMEDAP | Integracin B | FNC-TP | DDX3-IN-1 | Hypericin | Sennoside A | CK-666 | HIV-1 inhibitor-44 | Flavopiridol | Claficapavir | Atazanavir | 1-Deoxymannojirimycin hydrochloride | TC14012 | (Z)-9-Propenyladenine | Apabetalone | CCR5 antagonist 2 | 2F5 epitope | HIV-1 inhibitor-23 | Apelin-36(rat, mouse) | MIV-150
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。